123 related articles for article (PubMed ID: 19667696)
1. A patient-based approach to migraine clinical trials data. An overview.
Rapoport AM
Postgrad Med; 2005 May; 117(5 Suppl):3-6. PubMed ID: 19667696
[No Abstract] [Full Text] [Related]
2. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine.
Cephalalgia; 1991 Feb; 11(1):1-12. PubMed ID: 2036663
[No Abstract] [Full Text] [Related]
3. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
Sagkriotis A; Scholpp J
Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
[TBL] [Abstract][Full Text] [Related]
4. Migraine prophylaxis: key points for the practising clinician.
Moschiano F; D'Amico D; Bussone G
Neurol Sci; 2009 May; 30 Suppl 1():S33-7. PubMed ID: 19415423
[TBL] [Abstract][Full Text] [Related]
5. Moving forward - essential questions for the next 10 years.
Lipton RB; Sheftell FD
Headache; 2009 Feb; 49 Suppl 1():S43-6. PubMed ID: 19161565
[TBL] [Abstract][Full Text] [Related]
6. Clonidine for migraine.
Drug Ther Bull; 1972 Jul; 10(15):57-8. PubMed ID: 4561396
[No Abstract] [Full Text] [Related]
7. Dihydroergotamine: role in the treatment of migraine.
Schürks M
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
[TBL] [Abstract][Full Text] [Related]
8. [The therapy of migraine with methysergide in delayed-action form].
Kaeser HE
Praxis; 1965 Jul; 54(28):852-5. PubMed ID: 5319793
[No Abstract] [Full Text] [Related]
9. [Use of nicergoline (Sermion) in the treatment of migraine].
Prusiński A; Durko A; Selmaj K
Wiad Lek; 1984 Mar; 37(6):420-2. PubMed ID: 6385484
[No Abstract] [Full Text] [Related]
10. Tonabersat, a novel gap-junction modulator for the prevention of migraine.
Silberstein SD
Cephalalgia; 2009 Nov; 29 Suppl 2():28-35. PubMed ID: 19723123
[TBL] [Abstract][Full Text] [Related]
11. Margaritas... not science.
Rothrock JF
Headache; 2009 Jun; 49(6):962-4. PubMed ID: 19545258
[No Abstract] [Full Text] [Related]
12. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
Tepper SJ; Cleves C
Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
[TBL] [Abstract][Full Text] [Related]
13. Endpoints to evaluate efficacy of symptomatic drugs in migraine: what do patients want?
Pietrini U; De Luca M; Del Bene E
Headache; 2002 Oct; 42(9):948-9. PubMed ID: 12390628
[No Abstract] [Full Text] [Related]
14. Prospective study designs in outcomes research: the case of migraine.
Rothermich EA; Brod MI; Schonfeld WH; Rowland CR; Gomez-Mancilla B
Pharmacoeconomics; 2002; 20(11):715-25. PubMed ID: 12201791
[TBL] [Abstract][Full Text] [Related]
15. Ten years of rizatriptan: from development to clinical science and future directions.
Hargreaves RJ; Lines CR; Rapoport AM; Ho TW; Sheftell FD
Headache; 2009 Feb; 49 Suppl 1():S3-20. PubMed ID: 19161563
[TBL] [Abstract][Full Text] [Related]
16. In search of a migraine cure: a matter of heart and mind.
Qiu J
Lancet Neurol; 2008 Jul; 7(7):576-7. PubMed ID: 18565452
[No Abstract] [Full Text] [Related]
17. A clinical study of migraine evolution.
Kelman L
Headache; 2007 Sep; 47(8):1228-9; author reply 1229. PubMed ID: 17883539
[No Abstract] [Full Text] [Related]
18. Frovatriptan and data publication.
Tfelt-Hansen P
Headache; 2008 Oct; 48(9):1382-3. PubMed ID: 19006553
[No Abstract] [Full Text] [Related]
19. Exploitation masquerading as research.
Anthony WF
Headache; 2007 Oct; 47(9):1352-3. PubMed ID: 17927656
[No Abstract] [Full Text] [Related]
20. [Misleading and incorrect about the Norwegian Migraine Society and drug industry].
Migreneforbund N; Furulund S
Tidsskr Nor Laegeforen; 1999 Oct; 119(25):3811. PubMed ID: 10574063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
